Andere Sprachen Molecular Partners AG Nasdaq

Aktien

A3CSB5

US60853G1067

MOLN

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:00 16.04.2024			% 5 Tage	% 1. Jan.
3.91 ^USD	-1.01%		-3.69%	-6.46%

08:45	Morning Briefing - Markt Schweiz	AW
15.04.	Morning Briefing - Markt Schweiz	AW

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Principales informations avant-Bourse	08.04.
Court Dismisses Class Action Against Biopharmaceutical Company For Failing To Disclose Progress Of Competitor; Second Circuit Affirms Dismissal Of Putative Class Action Against Allergan; Eleventh Circuit Affirms That "Toxic" Lender Qualified As A "Dealer" Under The Exchange Act Due To High-Volume Trading; Delaware Court Of Chancery Invalidates Governance Rights In Stockholder Agreement	01.04.
Molecular Partners Publishes Invitation to Annual General Meeting 2024	26.03.
Molecular Partners Publishes Invitation to Annual General Meeting 2024	26.03.
Principales informations avant-Bourse	15.03.
Molecular Partners Swings to Loss in FY23; Revenue Down	15.03.
Molecular Partners financé jusque loin en 2026	14.03.
Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023	14.03.
Molecular Partners AG Reports Earnings Results for the Full Year Ended December 31, 2023	14.03.
Principales informations avant-Bourse	14.03.
US Court Dismisses Putative Class Action Against Molecular Partners	04.03.
Molecular Partners: procédure collective classée aux USA	01.03.
Molecular Partners Announces Dismissal of Class Action Lawsuit	01.03.
Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations	01.03.
Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations	01.03.
Molecular Partners Gears Up for 2024 Milestones, Including Data From Leukemia Treatment Trial	08.01.
Molecular Partners, Orano Med Team Up to Develop Radio-DARPin Therapeutics Against Cancer	08.01.
Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference	07.01.
Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies	05.01.
Molecular Partners AG and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies	05.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Molecular Partners AG Nasdaq

Aktien

A3CSB5

US60853G1067

MOLN

Andere Sprachen

Filter